Advertisement
ALXO vs AMRN
Which Stock Would AI Choose? ALX Oncology Holdings (ALXO) vs. Amarin Corporation (AMRN) Stock Comparison
Key Takeaways
- ALXO is a clinical-stage immuno-oncology developer with no commercial revenue, while AMRN is a commercial-stage cardiovascular company with an established, revenue-generating product.
- The two stocks occupy opposite ends of the biotech risk spectrum: ALXO is a binary, catalyst-driven opportunity, whereas AMRN offers a stabilized, cash-generating base with narrower growth.
- ALXO trades near multi-year lows despite a "Strong Buy" analyst consensus, while AMRN has delivered consecutive quarters of positive operating cash flow and remains debt-free.
- Sentiment differs sharply: ALXO's share price has been pressured by a broad drawdown in recent months, while AMRN's restructuring and European partnership have steadied investor perception.
- For additional context on each name, explore the ALXO Major News and ALXO Today's Price Move pages, as well as the AMRN Major News and AMRN Today's Price Move pages.
- For a data-driven lens on how automated strategies are positioning across the market, explore Trending AI Robots.
Introduction
This stock comparison examines two very different healthcare names: ALX Oncology Holdings (ALXO), a clinical-stage oncology biotech, and Amarin Corporation (AMRN), a commercial-stage cardiovascular pharmaceutical company. Although both trade on Nasdaq, their risk profiles, business models, and market positioning could hardly be more distinct. Investors weighing high-upside, high-uncertainty clinical catalysts against a steadier, revenue-backed turnaround story may find this side-by-side review useful. By focusing on recent performance, sentiment shifts, and observable fundamentals, this comparison aims to clarify where each company stands in the current market environment without favoring one over the other by design.
ALXO Overview and Recent Performance
ALX Oncology Holdings (ALXO) is a clinical-stage biotechnology company developing therapies for cancer. Its lead candidate, evorpacept, is a CD47-blocking therapeutic designed to be combined with anti-cancer antibodies, antibody drug conjugates (ADCs), and immune checkpoint inhibitors. A second program, ALX2004, is an EGFR-targeted ADC. Because the company is pre-revenue, its stock is driven primarily by clinical data readouts and financing events.
Recent market activity has been challenging for ALXO. The share price has declined meaningfully over the past month and quarter, trading well below its 52-week high and near the lower end of its recent range. This weakness has persisted even as the company reported encouraging early efficacy signals for evorpacept in HER2-positive cancer and secured additional Fast Track designations from the U.S. Food and Drug Administration (FDA). Analyst coverage remains notably constructive, with a "Strong Buy" consensus and average price targets implying substantial upside, but investors appear to be weighing the binary nature of clinical-stage development against those targets. The company's narrower net losses and a recent financing that extended its cash runway have provided some balance-sheet stability, though execution and regulatory risk remain central considerations.
AMRN Overview and Recent Performance
Amarin Corporation (AMRN) is a commercial-stage pharmaceutical company focused on cardiovascular health. Its primary product, Vascepa (icosapent ethyl), is marketed in the United States and, as Vazkepa, across Europe through partnerships. Unlike ALXO, Amarin generates recurring product, licensing, and royalty revenue and has shifted toward a leaner, asset-light operating model.
Over recent quarters, Amarin's performance has been defined by restructuring rather than explosive growth. The company completed a global reorganization targeting roughly $70 million in annual cost savings and signed a long-term licensing and supply agreement with Recordati to commercialize Vazkepa across 59 European countries. These moves have contributed to consecutive quarters of positive operating cash flow, a growing cash position, and a debt-free balance sheet. At the same time, reported revenue has faced pressure from generic competition in the U.S. and the transition to a partnered European model. Amarin's share price has been comparatively stable in recent weeks, reflecting a market that appears to value the company's improved cash discipline and durable, if modest, commercial base.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies from a broader library of hundreds of AI-powered trading bots covering thousands of tickers. Rather than listing every available bot, this section highlights only those whose configurations and recent performance are best aligned with current market conditions. Each bot operates with its own trading style, strategy, timeframe, performance statistics, and set of tickers, giving investors a range of approaches to explore. The selection is designed to surface strategies that are resonating in the prevailing environment, whether trend-following, mean-reversion, or momentum-based. For traders seeking a systematic, data-driven complement to manual analysis, reviewing the Trending AI Robots page offers a practical starting point.
Head-to-Head Comparison
The clearest contrast between ALXO and AMRN is stage of development. ALXO is pre-revenue and depends entirely on the success of clinical programs, which creates a wide range of possible outcomes driven by trial data. AMRN is a commercial entity with an approved product, meaning its risk is weighted toward pricing, competition, and partner execution rather than binary clinical results.
Growth drivers also diverge. ALXO's potential upside is tied to evorpacept and ALX2004 data readouts and potential future approvals, which could re-rate the stock sharply but carry no guaranteed timeline. AMRN's growth is more incremental, anchored in European market expansion under Recordati and modest U.S. prescription stability, with cost savings improving the bottom line. Risk factors reflect this divide: ALXO faces clinical, regulatory, and financing risk, while AMRN faces generic erosion, reimbursement pressure, and partner-reliance risk.
Market sentiment has moved in opposite directions. ALXO trades at a depressed valuation relative to analyst targets, signaling skepticism about the timeline to value realization. AMRN's steadier price action reflects a market rewarding cash flow and cost control despite limited top-line growth. Sector exposure also differs, with ALXO tied to oncology innovation and AMRN tied to cardiovascular and lipid-management markets.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and catalyst positioning, Tickeron's AI would likely favor AMRN in the current environment. The company's consecutive quarters of positive cash flow, debt-free balance sheet, completed restructuring, and comparatively stable price trend present a steadier profile than ALXO's more volatile, catalyst-dependent trading pattern. That said, ALXO's stronger analyst conviction and potential for outsized upside on clinical catalysts could shift relative positioning quickly if trial milestones materialize. This assessment reflects probabilistic, model-based analysis of current conditions rather than a definitive prediction of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALXO is a Hold and AMRN is a Hold.
ALXO's RSI Indicator ascends from oversold territory
The RSI Oscillator for ALXO moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 38 of the 44 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ALXO just turned positive on October 19, 2026. Looking at past instances where ALXO's MACD turned positive, the stock continued to rise in 31 of 40 cases over the following month. The odds of a continued upward trend are 77%.
Following a +11.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALXO advanced for three days, in 212 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 46 cases where ALXO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALXO as a result. In 76 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALXO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALXO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALXO entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. ALXO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.173) is normal, around the industry mean (3.498). P/E Ratio (-1.004) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALXO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AMRN's Stochastic Oscillator stays in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AMRN's RSI Indicator exited the oversold zone, 24 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for AMRN just turned positive on October 22, 2026. Looking at past instances where AMRN's MACD turned positive, the stock continued to rise in 40 of 54 cases over the following month. The odds of a continued upward trend are 74%.
Following a +1.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRN advanced for three days, in 183 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMRN as a result. In 78 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
AMRN broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AMRN entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.553) is normal, around the industry mean (-1.421). P/E Ratio (-9.675) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (3.220) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (1.554) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. AMRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
ALXO | AMRN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 36 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 63 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 92 | |
PRICE GROWTH RATING 1..100 | 79 | 71 | |
P/E GROWTH RATING 1..100 | 12 | 27 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMRN's Valuation (63) in the Pharmaceuticals Other industry is in the same range as ALXO (92) in the null industry. This means that AMRN’s stock grew similarly to ALXO’s over the last 12 months.
AMRN's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ALXO (100) in the null industry. This means that AMRN’s stock grew similarly to ALXO’s over the last 12 months.
AMRN's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as ALXO (98) in the null industry. This means that AMRN’s stock grew similarly to ALXO’s over the last 12 months.
AMRN's Price Growth Rating (71) in the Pharmaceuticals Other industry is in the same range as ALXO (79) in the null industry. This means that AMRN’s stock grew similarly to ALXO’s over the last 12 months.
ALXO's P/E Growth Rating (12) in the null industry is in the same range as AMRN (27) in the Pharmaceuticals Other industry. This means that ALXO’s stock grew similarly to AMRN’s over the last 12 months.
| ALXO | AMRN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 86% | 1 day ago 71% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 81% |
| Momentum ODDS (%) | 1 day ago 85% | 1 day ago 88% |
| MACD ODDS (%) | 1 day ago 77% | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 75% |
| Advances ODDS (%) | 3 days ago 86% | 2 days ago 74% |
| Declines ODDS (%) | 16 days ago 90% | 13 days ago 85% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 87% |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALXO’s FA Score shows that 1 FA rating(s) are green while AMRN’s FA Score has 1 green FA rating(s).
- ALXO’s FA Score: 1 green, 4 red.
- AMRN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALXO’s TA Score shows that 4 TA indicator(s) are bullish while AMRN’s TA Score has 4 bullish TA indicator(s).
- ALXO’s TA Score: 4 bullish, 4 bearish.
- AMRN’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALXO (@Biotechnology) experienced а -13.95% price change this week, while AMRN (@Pharmaceuticals: Major) price change was -2.49% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.33%. For the same industry, the average monthly price growth was +2.53%, and the average quarterly price growth was +7.15%.
Reported Earning Dates
ALXO is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (-1.33% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
ALXO and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALXO has been loosely correlated with MDGL. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ALXO jumps, then MDGL could also see price increases.
| Ticker / NAME | Correlation To ALXO | 1D Price Change % | ||
|---|---|---|---|---|
| ALXO | 100% | +0.90% | ||
| MDGL - ALXO | 56% Loosely correlated | +0.10% | ||
| AXON - ALXO | 45% Loosely correlated | +4.26% | ||
| AMRN - ALXO | 43% Loosely correlated | -0.34% | ||
| ARVN - ALXO | 38% Loosely correlated | -0.14% | ||
| FHTX - ALXO | 37% Loosely correlated | +10.00% | ||
More | ||||
AMRN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMRN has been loosely correlated with CNTB. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRN jumps, then CNTB could also see price increases.
| Ticker / NAME | Correlation To AMRN | 1D Price Change % | ||
|---|---|---|---|---|
| AMRN | 100% | -0.34% | ||
| CNTB - AMRN | 55% Loosely correlated | +0.98% | ||
| HRTX - AMRN | 44% Loosely correlated | -3.96% | ||
| MGNX - AMRN | 44% Loosely correlated | -4.13% | ||
| ALXO - AMRN | 43% Loosely correlated | +0.90% | ||
| ARWR - AMRN | 40% Loosely correlated | +0.73% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PSTP | 37.43 | 0.26 | +0.69% |
| Innovator Power Buffer Step-Up Strategy ETF (PSTP) | |||
| FLGR | 33.52 | 0.11 | +0.32% |
| Franklin FTSE Germany ETF (FLGR) | |||
| CGSD | 25.36 | -0.03 | -0.12% |
| Capital Group Short Duration Income ETF (CGSD) | |||
| WIP | 37.43 | -0.10 | -0.27% |
| State Street SPDR FTSE International Government Inflation-Protected Bond ETF (WIP) | |||
| REW | 12.50 | -0.87 | -6.51% |
| ProShares UltraShort Technology (REW) | |||